{
  "id": 14555197,
  "title": "Lipid Changes due to Low O-GlcNAc and the Downstream Consequences",
  "url": "https://urgent.news/2026/10/14/lipid-changes-due-to-low-o-glcnac-and-the-downstream-consequences",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-14T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.10.13.758586v1?rss=1"
  },
  "original_language": "en",
  "account": "O-GlcNAc transferase, a critical mammalian glycosyltransferase, adds O-GlcNAc to numerous proteins within cells. Dysregulation of this process is linked to various diseases, such as cancer and neurodegeneration. However, the impact of acute loss of O-GlcNAc is not well understood. To explore this, researchers used an OGT inhibitor, OSMI-4, alongside transcriptomic and lipidomic analyses on human cell lines. They found that the absence of O-GlcNAc caused alterations in lipid metabolism gene expression and changes in the lipidome. Specifically, unsaturated phosphatidylcholines, saturated lysophosphatidylcholines, and unsaturated storage lipids increased. Additionally, they observed an upsurge in lipid droplets. These findings indicate that polyunsaturated fatty acids (PUFAs) accumulate in cell membranes under low O-GlcNAc conditions. Cells counteract this by removing PUFAs from membrane lipids and storing them in lipid droplets. The study reveals that OSMI-4 treatment makes cells more susceptible to ferroptosis inducers, likely due to the accumulation of PUFAs in cell membranes that undergo peroxidation. Overall, the research underscores lipid remodeling as a crucial process mediating the effects of O-GlcNAc loss. It suggests that combining OGT inhibitors with ferroptosis inducers could potentially offer therapeutic advantages.",
  "summary": "O-GlcNAc transferase (OGT) is an essential mammalian glycosyltransferase that installs O-GlcNAc onto thousands of cytosolic and nuclear proteins. Dysregulated glycosylation by OGT is associated with disease states, including cancer and neurodegeneration. However, cellular consequences of acute loss of O-GlcNAc remain poorly understood. Here, we employed a cell-permeable small molecule inhibitor…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}